Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Dimerix Limited
  6. News
  7. Summary
    DXB   AU000000DXB7


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Dimerix Limited Announces Phase 3 DMX-200 Covid-19 Study Expands into Australia

10/14/2021 | 07:01pm EST

Dimerix Limited entered into an agreement with the NHMRC Clinical Trials Centre (CTC) at the University of Sydney to expand the CLARITY 2.0 clinical study to sites in Australia testing the Dimerix-developed drug candidate DMX-200 in COVID-19 patients with respiratory complications. An initial six sites will begin recruitment for the feasibility/Phase 3 study across New South Wales, Victoria and Queensland once regulatory and ethics approval is received. There are an estimated 26,448 active COVID-19 cases in Australia, and approximately 1,500 patients currently hospitalised. These numbers are expected to increase as border restrictions change over the coming months. Vaccines are critically important to reduce the severity of symptoms and spread of the disease. However, even as vaccination rates increase, it is anticipated that a significant proportion of the population will remain susceptible to COVID-19 because they are not vaccinated or do not get an adequate protective response from the vaccines. Therefore, it is still likely that a large number of people will get infected, with many ending up with COVID respiratory complications and potentially long-COVID, which refers to symptoms that extend long beyond recovery from the virus. As such, there remains a great need for treatments for patients with COVID-19 within Australia. The CLARITY 2.0 study, which is already approved and open for recruitment in India, will recruit an aggregate of 600 patients across both India and Australia. The NHMRC CTC will be the local sponsor in Australia, led by Professor Meg Jardine. Additional countries that could recruit patients for the study is also being investigated. The company's approach is based on a clear scientific rationale, unique and potentially complementary to others being investigated globally, and importantly if effective in this study, would likely be effective against any strain as well as potentially other pneumonias with a common mechanism of action.

ę S&P Capital IQ 2021
All news about DIMERIX LIMITED
01/10Dimerix Doses First Patients in Phase 3 Study of COVID-19 Respiratory Complications Dru..
01/10Dimerix Announces Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India
2021Dimerix Secures Australian Ethics Approval for Phase 3 Study of COVID-19 Drug Candidate..
2021Dimerix Limited Receives Ethics Approval in Australia for Phase 3 Covid-19 Study
2021Dimerix Secures Further Grant Funding for COVID-19 Drug Candidate
2021Dimerix Limited Announces It Has Been Awarded Further AUD 100,000 from the Australian G..
2021Dimerix Limited Advises That 662 Patients Have Now Been Recruited into the Feasibility/..
2021DIMERIX : Notification regarding unquoted securities - DXB
2021DIMERIX : Secures Ethics, Regulatory Approval for Phase 3 Kidney Disease Trial in Australi..
2021Dimerix Limited Announces First Approvals Received for Start of Phase 3 FSGS Trial
More news
Sales 2021 4,44 M 3,18 M 3,18 M
Net income 2021 -6,37 M -4,57 M -4,57 M
Net cash 2021 0,16 M 0,11 M 0,11 M
P/E ratio 2021 -6,06x
Yield 2021 -
Capitalization 75,4 M 53,9 M 54,1 M
EV / Sales 2020 26,7x
EV / Sales 2021 8,66x
Nbr of Employees -
Free-Float -
Duration : Period :
Dimerix Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DIMERIX LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Nina Webster Chief Executive Officer, MD & Director
Hamish George Chief Financial Officer & Secretary
James Howard Williams Non-Executive Chairman
David Packham Chief Medical Officer
Robert Shepherd Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
SEAGEN INC.-19.08%22 875